East Texas Clinical Trials

Texas Oncology cancer centers in east Texas participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the east Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the east Texas area are involved in several types of clinical trials:

Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in a Clinical Trial

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the east Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the east Texas area and talk to you doctor to determine which clinical trial is right for you.

Biliary Cancer

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Bladder Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: IV

Breast Cancer

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Cervical Cancer

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: IV

Colon Cancer

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Description: A Phase 1 Study of RGX-202-01 a Small Molecule Inhibitor of the Creatine Transporter SLC6a8 as a Single Agent and as Combination Therapy in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (RGX-202-001)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Endometrial Cancer

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: IV

Esophageal Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: IV

Fallopian Tube Cancer

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Gall Bladder Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Tyler

Phase: IV

Gastric Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: IV

Head and Neck Cancer

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Hematologic

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: IV

Leukemia

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: IV

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: III

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: III

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Liver Cancer

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: IV

Lung Cancer

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Controlled Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous NSCLC (HARMONi-3)(SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 of Gmma Delta T-Cell Infusions in combo w/subjects mNSCLC View

Description: Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta TCell Infusions in Combination with Low Dose Radiotherapy in Subjectswith Stage 4 Metastatic Non-Small Cell Lung Cancer.(DELTACEL-01)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 of Gmma Delta T-Cell Infusions in combo w/subjects mNSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 of Gmma Delta T-Cell Infusions in combo w/subjects mNSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Longview

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Paris

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IIIB

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: IIIB

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: IIIB

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: IIIB

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IIIB

Lymphomas

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: LTFU PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS. View

Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II/III

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: III

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Melanoma

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: IV

Mesothelioma

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Tyler

Phase: I/II

Myelodysplastic Syndrome

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: IV

Myelofibrosis

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I/III

Title: An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I

Myelomas

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: IV

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Longview

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: II

Ovarian Cancer

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: IV

Pancreatic Cancer

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Description: A PHASE II RANDOMIZED OPEN-LABEL TRIAL OF NAB-PACLITAXEL +GEMCITABINE WITH OR WITHOUT BOTENSILIMAB (Agen1181) IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE PROGRESSED ON PRIOR 5FU + LEUCOVORIN+ IRINOTECAN +OXALIPLATIN (FOLFIRINOX)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Description: An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab compared to chemotherapy alone for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II

Peritoneal Cancer

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Prostate Cancer

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: IV

Rectal Cancer

Title: Ph2 Epidemi Colon Cancer View

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: IV

Renal Cancer

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: IV

Skin Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Tyler

Phase: IV

Solid Tumors

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Thyroid Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: IV

Urothelial Cancer

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Urothelial Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Urothelial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II/III

Waldenström macroglobulinemia

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Tyler

Phase: II

Texas Oncology-Longview

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Longview

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph1 of Gmma Delta T-Cell Infusions in combo w/subjects mNSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: I

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Longview

Phase: IV

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Longview

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: IV

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Urothelial Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Longview

Phase: II

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II/III

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Longview

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: III

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: III

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: IIIB

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: II

Texas Oncology-Longview Cancer Center

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1 of Gmma Delta T-Cell Infusions in combo w/subjects mNSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IIIB

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Texas Oncology-Palestine Cancer Center

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Urothelial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IIIB

Texas Oncology-Paris

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Paris

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Paris

Phase: IV

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: IV

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: IV

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Paris

Phase: II

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Paris

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: III

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: IIIB

Texas Oncology-Tyler

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 Epidemi Colon Cancer View

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 of Gmma Delta T-Cell Infusions in combo w/subjects mNSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: LTFU PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS. View

Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: IV

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 Epidemi Colon Cancer View

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Tyler

Phase: II

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I/III

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: IIIB

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

No Phase

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Longview

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Paris

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 of Gmma Delta T-Cell Infusions in combo w/subjects mNSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 of Gmma Delta T-Cell Infusions in combo w/subjects mNSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 of Gmma Delta T-Cell Infusions in combo w/subjects mNSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 FIH RGX-202-01 SLC6A8 GI malig View

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I

Phase I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Mesothelioma

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Phase I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I/III

Phase II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Longview

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Study of REC-4881 with Advanced or met cancer with AXINI or APC mutation View

Description: A PHASE 2 OPEN LABEL STUDY OF REC-4881 IN PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER WITH AXIN1OR APC MUTATION (REC-4881-221)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Tyler

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Phase II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: Ph2 Epidemi Colon Cancer View

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: LTFU PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS. View

Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: Ph2 Epidemi Colon Cancer View

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Urothelial Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Urothelial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II/III

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II/III

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Phase III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Share:

East Texas Clinical Trials

Benefits and Risks of Participating in a Clinical Trial

Clinical Trial Eligibility